At Bio Vantage, our mission is to provide high-quality equity reports primarily on biotech and pharmaceutical companies worldwide. In our view, fundamental analysis of biopharmaceutical companies requires expertise in evaluating clinical trial data and drug pipelines, as these events can drive the underlying equity value of such companies going forward. Equally important is the ability to forecast future revenues, earnings growth, and cash flows using financial modeling tools in order to derive a fair value for the analyzed company. With the fundamental value as an anchor or price target, investors can make profits from a variety of trading instruments at any given time, through trading stocks or options. While our expertise largely concerns biotech and pharmaceutical companies, our investment principles are centered on diversification, asset allocation, risk management, and portfolio strategies. Thus, our investments and analyses also include other sectors, including technology, financials, consumer products, energy, and commodities. Bio Vantage's analysts have over 15 years of experience in the biomedical field and in drug discovery research, with several patents and over 80 publications. We are CFA candidates and lifelong investors.